Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
23ME-01473 in advanced solid malignancies
NCT06290388Phase 2Terminated
- Sponsor
- 23andMe
- Start
- Mar 2024
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 23me-01473 in solid tumor, sponsored by 23andMe. Started Mar 2024; status: terminated.
02
Drugs
23me-01473
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06290388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06290388.